
Seamus Fernandez
Stock Analyst at Guggenheim
(4.96)
# 108
Out of 5,136 analysts
430
Total ratings
64.7%
Success rate
28.8%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $57 | $27.80 | +105.04% | 12 | Nov 16, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $26 | $10.13 | +156.66% | 7 | Nov 15, 2026 | |
| SEPN Septerna | Rated: Buy | $51 → $65 | $41.67 | +55.99% | 4 | Nov 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $143 → $147 | $107.48 | +36.77% | 17 | Nov 4, 2026 | |
| RTSN Retension Pharmaceuticals | Initiated Coverage: Buy | $55 | $11.46 | +379.93% | 1 | Nov 2, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $62.93 | +19.18% | 52 | Oct 29, 2026 | |
| ACRS Aclaris Therapeutics | Reiterated: Buy | $12 | $3.61 | +232.87% | 5 | Oct 28, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $170 | $125.85 | +35.08% | 1 | Oct 28, 2026 | |
| ARQT Arcutis Biotherapeutics | Rated: Buy | $38 → $44 | $27.15 | +62.06% | 16 | Oct 19, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $125 | $61.61 | +102.89% | 16 | Oct 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $53.12 | +182.38% | 17 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.32 | +321.69% | 8 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,273 → $1,284 | $1,431.67 | -10.31% | 63 | Sep 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.48 | - | 8 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $52 | $14.53 | +257.88% | 9 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.31 | - | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 16,500p → 16,200p | 14,034p | +15.43% | 20 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $48.39 | - | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $10.49 | +185.99% | 3 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $18.57 | +653.90% | 7 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €101.00 | €88.32 | n/a | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $41.60 | n/a | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.56 | n/a | 12 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,929.50 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $50.41 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 → $130 | $144.46 | n/a | 36 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 → $83 | $23.47 | n/a | 5 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.5377 | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $149.70 | n/a | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $135.76 | n/a | 4 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $160.20 | n/a | 16 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.07 | n/a | 1 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.22 | n/a | 2 | Sep 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 | $28.86 | n/a | 16 | Sep 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $8.45 | n/a | 1 | Aug 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $3.20 | n/a | 3 | Aug 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $159.73 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $462.32 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $952.40 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $282.55 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $56 | $30.15 | n/a | 5 | Jun 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 | $28.59 | n/a | 1 | Mar 7, 2016 |
Amylyx Pharmaceuticals
Nov 16, 2026
Reiterated: Buy
Price Target: $57
Current: $27.80
Upside: +105.04%
Sagimet Biosciences
Nov 15, 2026
Reiterated: Buy
Price Target: $26
Current: $10.13
Upside: +156.66%
Septerna
Nov 6, 2026
Rated: Buy
Price Target: $51 → $65
Current: $41.67
Upside: +55.99%
Rhythm Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $143 → $147
Current: $107.48
Upside: +36.77%
Retension Pharmaceuticals
Nov 2, 2026
Initiated Coverage: Buy
Price Target: $55
Current: $11.46
Upside: +379.93%
Bristol-Myers Squibb Company
Oct 29, 2026
Reiterated: Buy
Price Target: $75
Current: $62.93
Upside: +19.18%
Aclaris Therapeutics
Oct 28, 2026
Reiterated: Buy
Price Target: $12
Current: $3.61
Upside: +232.87%
Kymera Therapeutics
Oct 28, 2026
Reiterated: Buy
Price Target: $170
Current: $125.85
Upside: +35.08%
Arcutis Biotherapeutics
Oct 19, 2026
Rated: Buy
Price Target: $38 → $44
Current: $27.15
Upside: +62.06%
Vaxcyte
Oct 18, 2026
Reiterated: Buy
Price Target: $125
Current: $61.61
Upside: +102.89%
Oct 12, 2026
Reiterated: Buy
Price Target: $150
Current: $53.12
Upside: +182.38%
Sep 28, 2026
Reiterated: Buy
Price Target: $14
Current: $3.32
Upside: +321.69%
Sep 17, 2026
Reiterated: Buy
Price Target: $1,273 → $1,284
Current: $1,431.67
Upside: -10.31%
Aug 31, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.48
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: $48 → $52
Current: $14.53
Upside: +257.88%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.31
Upside: -
Jul 9, 2026
Reiterated: Buy
Price Target: 16,500p → 16,200p
Current: 14,034p
Upside: +15.43%
Jul 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $48.39
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: $30
Current: $10.49
Upside: +185.99%
May 7, 2026
Reiterated: Buy
Price Target: $140
Current: $18.57
Upside: +653.90%
Oct 8, 2025
Reiterated: Buy
Price Target: €110.00 → €101.00
Current: €88.32
Upside: n/a
Apr 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $41.60
Upside: n/a
Apr 3, 2025
Rated: Hold
Price Target: n/a
Current: $1.56
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $1,929.50
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $50.41
Upside: n/a
Jan 29, 2024
Reiterated: Buy
Price Target: $125 → $130
Current: $144.46
Upside: n/a
Oct 14, 2022
Reiterated: Buy
Price Target: $250 → $83
Current: $23.47
Upside: n/a
Dec 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.5377
Upside: n/a
Dec 7, 2021
Downgraded: Hold
Price Target: n/a
Current: $149.70
Upside: n/a
Feb 25, 2020
Downgraded: Hold
Price Target: n/a
Current: $135.76
Upside: n/a
Oct 8, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $160.20
Upside: n/a
Oct 17, 2017
Initiated Coverage: Buy
Price Target: $13
Current: $3.07
Upside: n/a
Sep 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $4.22
Upside: n/a
Sep 8, 2016
Reiterated: Hold
Price Target: $37
Current: $28.86
Upside: n/a
Aug 24, 2016
Reiterated: Buy
Price Target: $108
Current: $8.45
Upside: n/a
Aug 9, 2016
Reiterated: Buy
Price Target: $52
Current: $3.20
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $159.73
Upside: n/a
Jul 15, 2016
Rated: Hold
Price Target: n/a
Current: $462.32
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $952.40
Upside: n/a
Jun 14, 2016
Reiterated: Buy
Price Target: $125
Current: $282.55
Upside: n/a
Jun 13, 2016
Reiterated: Hold
Price Target: $56
Current: $30.15
Upside: n/a
Mar 7, 2016
Downgraded: Hold
Price Target: $4
Current: $28.59
Upside: n/a